Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Agaricia lamarcki

ABSTRACT: Agaricia lamarcki Transcriptome or Gene expression

PROVIDER: PRJNA435937 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6782832_1.fastq.gz	Fastqsanger.gz
	SRR6782832_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

Spirobranchus lamarcki

Project description:Spirobranchus lamarcki Transcriptome or Gene expression

| PRJNA169539 | ENA

Spirobranchus lamarcki

Project description:Spirobranchus lamarcki regeneration transcriptomes

| PRJNA433343 | ENA

Spirobranchus lamarcki

Project description:Annelid Genome Sequencing (Pomatoceros lamarcki)

| PRJNA275760 | ENA

Project description:Reduced representation (nextRAD) sequences for Agaricia grahamae and A. lamarcki from the Southern Caribbean

| PRJNA801008 | ENA

Spirobranchus lamarcki

Project description:Pomatoceros lamarckii overview

| PRJNA169651 | ENA

Biomarks of Resistance to Cetuximab in Colorectal Cancer

Project description:Interventions: A group:Before using cetuximab;B group:After progression of disease:no Primary outcome(s): KRAS gene sequence;NRAS gene sequence;BRAF gene sequence;PIK3CA gene sequence;EGFR gene sequence;EGFR gene copy numbers;EGFR expression;Her2 expression;c-Met expression;PTEN expression Study Design: historical control

| 2671639 | ecrin-mdr-crc

Project description:Shallow Agaricia spp. in Curacao

| PRJNA1120949 | ENA

Project description:Genetic diversity of Agaricia undata in Colombia

| PRJNA385083 | ENA

TR study of ‘multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer&quot

Project description:Primary outcome(s): Cancer-related gene alteration, expression of protein, and expression of RNA

| 2645675 | ecrin-mdr-crc

TR study of ‘A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer (BRAVERY study)&quot

Project description:Primary outcome(s): cancer-related gene alteration, gene expression, microsatellite instability, BRAF mutant allele frequency

| 2646701 | ecrin-mdr-crc